Bumrungthai Sureewan, Ekalaksananan Tipaya, Kleebkaow Pilaiwan, Pongsawatkul Khajohnsilp, Phatnithikul Pisit, Jaikan Jirad, Raumsuk Puntanee, Duangjit Sureewan, Chuenchai Datchani, Pientong Chamsai
Division of Biopharmacy, Faculty of Pharmaceutical Sciences, Ubon Ratchathani University, Ubon Ratchathani 34190, Thailand.
Division of Microbiology and Parasitology, School of Medical Sciences, University of Phayao, Phayao 56000, Thailand.
Diagnostics (Basel). 2023 Mar 13;13(6):1084. doi: 10.3390/diagnostics13061084.
The current practice of determining histologic grade with a single molecular biomarker can facilitate differential diagnosis but cannot predict the risk of lesion progression. Cancer is caused by complex mechanisms, and no single biomarker can both make accurate diagnoses and predict progression risk. Modelling using multiple biomarkers can be used to derive scores for risk prediction. Mathematical models (MMs) may be capable of making predictions from biomarker data. Therefore, this study aimed to develop MM-based scores for predicting the risk of precancerous cervical lesion progression and identifying precancerous lesions in patients in northern Thailand by evaluating the expression of multiple biomarkers. The MMs (Models 1-5) were developed in the test sample set based on patient age range (five categories) and biomarker levels (cortactin, p16, and Ki-67 by immunohistochemistry [IHC], and HPV / ribonucleic acid (RNA) by in situ hybridization [ISH]). The risk scores for the prediction of cervical lesion progression ("risk biomolecules") ranged from 2.56-2.60 in the normal and low-grade squamous intraepithelial lesion (LSIL) cases and from 3.54-3.62 in cases where precancerous lesions were predicted to progress. In Model 4, 23/86 (26.7%) normal and LSIL cases had biomolecule levels that suggested a risk of progression, while 5/86 (5.8%) cases were identified as precancerous lesions. Additionally, histologic grading with a single molecular biomarker did not identify 23 cases with risk, preventing close patient monitoring. These results suggest that biomarker level-based risk scores are useful for predicting the risk of cervical lesion progression and identifying precancerous lesion development. This multiple biomarker-based strategy may ultimately have utility for predicting cancer progression in other contexts.
目前使用单一分子生物标志物确定组织学分级的做法有助于鉴别诊断,但无法预测病变进展风险。癌症是由复杂机制引起的,没有单一生物标志物能够既做出准确诊断又预测进展风险。使用多种生物标志物进行建模可用于得出风险预测分数。数学模型(MMs)或许能够根据生物标志物数据进行预测。因此,本研究旨在通过评估多种生物标志物的表达,开发基于MMs的分数,以预测泰国北部患者宫颈癌前病变进展风险并识别癌前病变。基于患者年龄范围(五类)和生物标志物水平(通过免疫组织化学[IHC]检测的皮层肌动蛋白、p16和Ki-67,以及通过原位杂交[ISH]检测的人乳头瘤病毒/核糖核酸[RNA]),在测试样本集中开发了MMs(模型1-5)。预测宫颈病变进展的风险分数(“风险生物分子”)在正常和低级别鳞状上皮内病变(LSIL)病例中为2.56 - 2.60,在预测癌前病变会进展的病例中为3.54 - 3.62。在模型4中,23/86(26.7%)的正常和LSIL病例的生物分子水平提示有进展风险,而5/86(5.8%)的病例被识别为癌前病变。此外,使用单一分子生物标志物进行组织学分级未能识别出23例有风险的病例,从而无法对患者进行密切监测。这些结果表明,基于生物标志物水平的风险分数有助于预测宫颈病变进展风险并识别癌前病变发展。这种基于多种生物标志物的策略最终可能在其他情况下用于预测癌症进展。